TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00969436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biological's investigational MMRV vaccine 208136
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biological's investigational MMRV vaccine 208136
Description: Subcutaneous injection
Study: NCT04681170

Intervention type: DRUG
Group type: OTHER
Intervention: Lomitapide
Description: 2mg,5mg, 10mg and 20mg capsules
Study: NCT00969436

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix™
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix™
Description: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varilrix™
Description: Subcutaneous injection
Study: NCT01669408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold crystalloid infusions, 0.9%NaCl or Ringer's solution
Description: Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
Study: NCT03399357

Intervention type: BIOLOGICAL
Intervention: Influenza Vaccine
Description: Inactivated Trivalent Influenza Vaccine (IIV3) 2017 containing: A (H1N1): an A/Michigan/45/2015 (H1N1) - like virus (new strain); A (H3N2): an A/Hong Kong/4801/2014 (H3N2) - like virus; B/Brisbane/60/2008 - like virus
Study: NCT03612323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-ligamentary Piroxicam
Description: Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-ligamentary Articaine
Description: Articaine is a local anesthetic agent , has been reported to be an effective anesthetic in controlling pain during root canal treatment
Study: NCT02927275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Standing Modality
Description: Cognitive performance when standing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Biking Modality
Description: Cognitive performance when biking slowly

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Walking Modality
Description: Cognitive performance when walking at 1mph

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No Intervention: Seated Modality
Description: Cognitive performance when sitting.
Study: NCT01632644

Intervention type: OTHER
Intervention: Survey/Interview
Description: Each group will be surveyed and interviewed.

Intervention type: OTHER
Intervention: Survey/Interview
Description: Each group will be surveyed and interviewed.
Study: NCT01187459

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 10 ug/day Vitamin D, taken for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 50 ug/day Vitamin D, taken for 6 months.
Study: NCT04279145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: swan ganze catheter /echocardiography
Description: Right heart catheterization and mixed venous blood samples will be obtained for ABG, biomarkers (troponin , uric acid and micro RNA).~Each subject will have echocardiography, 6 MWD, clinical functional class and blood sample at the day of right heart catheterization or at least less than week of right heart catheterization
Study: NCT02840786

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plaque excision system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon and Stent
Study: NCT02382848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Prazosin-matched placebo pill

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prazosin
Description: A starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
Study: NCT02382848

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prazosin-matched placebo pill
Study: NCT00831701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4 mg Tamsulosin once daily for 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo pill per day for 21 days or until stone expulsion
Study: NCT01595581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: 8 weeks of testosterone administration beginning 2 weeks before ACL surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 weeks of saline administration beginning 2 weeks before ACL surgery
Study: NCT03161860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised citizen assistance for social participation(APIC)
Description: The APIC involves a non-professional attendant who, after 2 to 5 days of training, provides a two to three-hour stimulation session each week over a six to eighteen-month period targeting significant social and leisure activities that are otherwise difficult for older adults to accomplish.
Study: NCT01261169

Intervention type: DRUG
Intervention: Myfortic
Description: Myfortic in uveitis
Study: NCT00693654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarna
Description: Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (\&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetaphil
Description: Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid
Study: NCT00320138

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture, using Chinese Medicine methodology
Description: 4 weeks of 2/week treatments (8 total); 4 standardized and 4 individualized treatments
Study: NCT02079935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy
Description: Following group-modified protocol for cognitive behavioral therapy, CBT, first described by Fairburn 2008, modified by Modum Bad, Norway.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity and Dietary Therapy
Description: Guided physical activity and dietary therapy, to (re-)introduce a more healthy lifestyle and help stabilizing a healthy weight. A detailed manual will be published.
Study: NCT01557881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging with positron emission tomography scanning
Description: University Hospitals Seidman Cancer Center \[SCC\] will house the Philips Ingenuity TF PET/MR, which is a hybrid scanner that merges magnetic resonance imaging with positron emission tomography scanning. University Hospitals is one of only five hospitals in the world with this technology. The PET/MRI system consists of two imaging scanners used sequentially as in PET/CT. The 3Tesla MRI component provides the high resolution that is necessary for soft tissue contrast and functional information on perfusion, diffusion, or metabolism. PET provides information about cellular metabolism and receptor status.
Study: NCT03362697

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: The Probiotic group will receive Sachet 1 - contains an instant cranberry drink, consisting of xylitol, monosodium citrate, cranberry aroma, cranberry extract, grape-skin extract, xanthan gum, acesulfame potassium and zinc gluconate and Sachet 2 - contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin. Both Sachets should be administered Day 1-14, twice per day This group will also receive for Placebo for Antibiotic treatment day 1-7, twice per day
Study: NCT03626389

Intervention type: OTHER
Intervention: Physiotherapy
Study: NCT03362697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Patient in this group will receive for 7 days Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick. This group will also receive for placebo for probiotics 2 sachets for 14 days
Study: NCT00630227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biologic Lung Volume Reduction
Description: 20 mL Hydrogel
Study: NCT01096966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine TTS (Bupivacaine Patch)
Description: Contains bupivacaine base, in a flexible and rectangular-shaped, transdermal, delivery system. Three patches applied to the lower back every 72 hours for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.
Study: NCT02643823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hUC-MSC + DMARDs
Description: Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARDs
Description: Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
Study: NCT01390207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16mm triggering
Description: Final oocyte maturation will be achieved by administration of 10.000 IU of hCG (Pregnyl®). Randomization will be into 2 groups:~• Group A (early hCG group): hCG will be administrated as soon as ≥ 3 follicles ≥ 16mm were present on ultrasound.
Study: NCT04593459

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: See Arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride
Description: See Arm description

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic Placebo
Description: See Arm description
Study: NCT03985007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDIAG regimen
Description: Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.
Study: NCT02626637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity coaching
Description: Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
Study: NCT00739544

Intervention type: OTHER
Group type: OTHER
Intervention: 1
Description: Testing with thermal sensor testing device, von Frey filaments, cotton wisp, turning fork, pressure gauge device
Study: NCT03016247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRUST Intervention
Description: The TRUST intervention will be guided by Rotenberg's Framework of Interpersonal Trust 3. The TRUST group will meet with an interventionist trained in weight self-management for eight 90-minute weekly sessions. Each session will include adolescent/parent trust-building exercises (honesty, reliability, emotional connection), didactic content, experiential skills developing (nutrition label reading), behavior-change goal-setting, and problem-solving.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Single meeting with a Nutritionist for physical activity and eating counseling.
Study: NCT03036891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol 25 MG Oral Tablet [Movantik]
Description: Patients will be given the study drug (Movantik 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Patients will be given Placebo (Placebo 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
Study: NCT01906814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 cycles chemotherapy
Description: Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for three cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 cycles chemotherapy
Description: Chemotherapy: vincristine 0.05 mg/kg (or 1.5 mg/m2 for children ≥ 3 years of age) on Day 1, carboplatin 18.6 mg/kg (or 560 mg/m2 for children ≥ 3 years of age) on Day 1, etoposide 5.0 mg/kg/day (or 150 mg/ m2 for children ≥ 3 years of age) on Days 1 and 2 and 2. Cycles were repeated every 21 days for six cycles.
Study: NCT00518323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 3 mg or 6 mg tablet once daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 1.5 mg tablet once daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 6 mg or 12 mg tablet once daily for 6 weeks
Study: NCT02201186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuka honey enema
Description: Study patients diagnosed with acute pouchitis will perform manuka honey enemas twice a day for 30 days.
Study: NCT01481233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.6 mg bid to a maximum of 1.2 mg bid
Study: NCT03742154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline 0.5 MG
Description: varenicline comes in bottles of 56 - 0.5 mg pills
Study: NCT04056442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol , synthetic form
Description: Cannabidiol ( synthetic form)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Olive Oil Solution, 5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive Oil Solution, 5%
Study: NCT02596581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal treatment
Description: scaling and root planing were performed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal treatment
Description: scaling and root planing were performed
Study: NCT02015650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C/ 5-Fluorouracil
Description: Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
Study: NCT03711487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foeniculum Vulgare Seed Ironing
Description: Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, twice daily on postoperative days 2 to 3. The medicine bag can be heated and reused after it cool down.
Study: NCT01917201

Intervention type: PROCEDURE
Group type: OTHER
Intervention: IVUS-guided group
Description: The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under IVUS-control: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS is being used. If criteria of optimal implantation were not achieved, additional impact is being made: larger balloon, higher pressure, sufficient time of impact. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. During OCT possible problems corresponding to stenting are being fixed. An additional impact based on OCT data is not being used.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-IVUS group
Description: The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under angiography control. After postdilatation control OCT is carried out. During OCT possible problems corresponding to stenting (malapposed struts, separate beams, a prolapse of fiber, microthrombosis) are being fixed. An additional impact based on OCT data is not being used.
Study: NCT00940394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mutual support group
Description: bi-weekly, 12-session, family-led mutual support group
Study: NCT02967406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 x 4 lifestyle modification
Description: Participants in the intervention group will be given 4x4 lifestyle modification intervention, which will address four health behaviors (diet, physical activity, alcohol drinking and smoking) at four different levels: individual, household, knowledge management and community levels. A new computer program called 'iActive' adapted from the GPAQ with add-on functions to allow real-time assessment and presentation of the energy expenditure along with recommendations specific to each individual will be used. Dietary counseling will be given individually following assessment using a new dietary assessment program called Dietary Assessment Scanning Calculator. Home visit will be done every 3 months by responsible nurses and village health volunteers. Knowledge management will be done through meetings between participants and villages with support from trained nurses. Situation analysis and community action will be encouraged to address four health behaviors.
Study: NCT02176226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntelliCare
Description: Behavioral interventions for depression and anxiety via a mobile phone application, IntelliCare.
Study: NCT03702452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional rehabilitation nursing program
Description: According to the modified Barthel index score, the patients' function was divided into four parts Level,each level has different kinds of rehabilitation nursing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: The rehabilitation were given by the rehabilitation therapist based on the patient's condition, such as, bridge movement,limb passive motion, limb active motion,turn over,sit upw,walk, and so on.
Study: NCT01815866

Intervention type: PROCEDURE
Intervention: CF with culturable NTM
Description: CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
Study: NCT01815099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS Treatment
Description: Either 10 or 15 rTMS sessions (2 or 3 times/week for 5 weeks, respectively)
Study: NCT01292733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Tumor Marker Analysis
Description: Performed every 6 months, these blood samples will be drawn to measure the concentration of CA125 tumor marker. Remaining samples will be stored in a specimen repository for use in future research for ovarian and breast cancer tumor markers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transvaginal Ultrasound
Description: Performed annually, these pelvic ultrasounds will be used used to look for 1) enlargement of one or both ovaries or 2) suspicious or indeterminate morphometric parameters, determined by the presence of intracystic papillations, and/or mural nodularity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Status Questionnaire
Description: Performed every 6 months, these questionnaires will ask about your health and medical history, environmental exposures, and family history.
Study: NCT04049344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine; Oxaliplatin
Description: Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
Study: NCT04216628

Intervention type: OTHER
Group type: OTHER
Intervention: Amniotomy
Description: Artificial rupturing of membranes and IV infusion of Oxytocin

Intervention type: OTHER
Group type: OTHER
Intervention: Amniotomy
Description: Artificial rupturing of membranes and IV infusion of Oxytocin
Study: NCT02367157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kenzo Kase Method

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping